Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Search

Total 93 results found. Search for [ Indian Pharmaceutical Alliance ]

Results 1 to 21 of 93
E Kumar Sharma
February 22, 2019
D G Shah had a larger imprint on the pharma industry than what his job title -- secretary general of the Indian Pharmaceutical Alliance (IPA) -- could convey.


PB Jayakumar
February 22, 2019
An expert on IP rights and international trade relations related to pharmaceuticals, Shah had fought for Indian generic industry in several WTO and many other international pharma and IPR deliberations.


E Kumar Sharma
New Delhi, February 19, 2019
DG Shah, Secretary General of the Indian Pharmaceutical Alliance, sees problems on three fronts: pricing, regulatory and exports.


PTI
December 31, 2018



PB Jayakumar
New Delhi, November 26, 2018
Market changes and increased regulatory oversight in the US have hurt Lupin, but India's third-biggest drug maker is making efforts to come back.


PB Jayakumar
New Delhi, October 29, 2018
A big transformation is happening in the global generic pharmaceutical industry. As a result, stocks of most major drug companies have done badly in the past one year.


E Kumar Sharma
New Delhi, June 12, 2018
Indian pharma is on edge with an expected pharma pricing overhaul, but nothing is known yet on the shape of things to come.


BusinessToday.In
June 10, 2018
During the summit, India signed various agreements with the member countries including host nation China. Prime Minister Modi held nearly half a dozen bilateral meetings with leaders of other SCO countries.


PB Jayakumar
New Delhi, March 7, 2018
The Indian pharmaceutical industry, earlier reeling under the regulatory scanner of the USFDA, is learning from its mistakes.


PB Jayakumar
New Delhi, March 5, 2018
Out of the 192 inspections held by the US FDA in India in 2017, only eight were referred for Official Action indicated (OAI) or found out objectionable conditions at the audit site


E Kumar Sharma
New Delhi, February 1, 2018
The measures announced in the budget could trigger a rise in demand for medicines but those within the Indian pharma feel this alone may not help.


E Kumar Sharma
New Delhi, January 12, 2018
Many companies, with some leading players, are already coping with challenges around price erosion in generics, erosion of base business resulting from new competition and buyer consolidation in their biggest global market, the US.


PTI
December 27, 2017



P.B. Jayakumar
New Delhi, December 11, 2017
Margin erosion and regulatory hurdles are hitting Indian pharma companies hard in their biggest market.


Anilesh S. Mahajan
New Delhi, December 11, 2017
India clamps down on Chinese imports citing the one-sided nature of the engagement. But the process of weaning away industry from cheaper imports will not be easy.


E. kumar sharma
New Delhi, December 11, 2017
Indian pharma companies are facing strong headwinds, but they are also exploring every new opportunity to ensure a quick recovery.


E. Kumar Sharma
New Delhi, November 25, 2017
Pharma stocks continue to underperform as policy uncertainty adds to the toll taken by USFDA and market challenges.


E Kumar Sharma
November 21, 2017
The US Food and Drug Administration (USFDA) seems to have sent out a strong message to pharmaceutical companies in India on the need to adhere to a quality culture and on matters relating to data integrity.


E Kumar Sharma
New Delhi, November 12, 2017
Every business has the right to adopt legitimate practises to protect their own interest. Right? But a recent article argues that going beyond the patent act, which permits research and development during the life of a patent, some innovator drug companies are busy trying to block this.


E Kumar Sharma
New Delhi, November 6, 2017
Why should there be the Goods and Services Tax on materials that cannot be sold? That is the question, the Indian pharmaceutical industry, is hoping will get addressed in the final tweaking of the GST provisions.


PAGES 1 OF 5  12345